Inflammatory Bowel Disease n = 1432 | Crohn’s Disease n = 548 | Ulcerative Colitis n = 585 | IBD-U n = 299 | |
---|---|---|---|---|
Boys, n (%) | 802 (56%) | 319 (58%) | 317 (54%) | 166 (56%) |
Age (y); mean (SD) | ||||
at identification | 10 (4) | 11 (4) | 10 (4) | 9 (4) |
in 2010 | 14 (3) | 14 (3) | 14 (3) | 14 (3) |
Age groups in 2010 | ||||
0–9 years d | 156 (11%) | 51 (9%) | 71 (12%) | 34 (11%) |
10–17 years | 1276 (89%) | 497 (91%) | 514 (88%) | 265 (89%) |
Presence of diseases considered to be extra-intestinal manifestations | 281 (20%) | 115 (21%) | 91 (16%) | 75 (25%) |
IBD-related in- and outpatient visits in 2010 | ||||
Outpatient visits | 1199 (84%) | 451 (82%) | 492 (84%) | 256 (86%) |
Inpatient visits | 310 (22%) | 128 (23%) | 121 (21%) | 61 (20%) |
Major IBD-related surgery | ||||
In 2010 | 35 (2%) | 23 (4%) | 7 (1%) | 5 (2%) |
During 1993-2010c | 78 (5%) | 28 (5%) | 23 (4%) | 27 (9%) |
Colectomy | 36 (3%) | 1 (0.2%) | 18 (3%) | 17 (6%) |
Intestinal surgery | 45 (3%) | 27 (5%) | 5 (1%) | 13 (4%) |
Rectal surgery | 6 (0.4%) | 1 (0.2%) | 2 (0.3%) | 3 (1%) |
Minor bowel surgery | 83 (6%) | 58 (11%) | 6 (1%) | 19 (6%) |
IBD-related drug treatment | ||||
In 2010 | 1213 (85%) | 443 (80%) | 502 (86%) | 262 (88%) |
Aminosalicylates | 1 065 (74%) | 370 (68%) | 472 (81%) | 223 (75%) |
Steroids | 593 (41%) | 203 (37%) | 257 (44%) | 133 (44%) |
Immunosuppressants (incl. biologics) a | 666 (47%) | 307 (56%) | 209 (36%) | 150 (50%) |
During 2005-2010b | 1333 (93%) | 500 (91%) | 541 (92%) | 292 (98%) |